Sign in
4

Changes in Ownership

VERTEX PHARMACEUTICALS INC / MA Filed Acc 0000875320-26-000129

CEO & President sold 40,000 shares at an average $493.47 ($19,738,855)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Kewalramani Reshma · CEO & President

Table I: Non-derivative

13 lines
Date Transaction Shares Price Value Owned after D/I
2026-02-27 Sale : show line 1 in the form 10b5-1 −400 $479.75 $191,900 137,878 D
2026-02-27 Sale : show line 2 in the form 10b5-1 −120 $481.50 $57,780 137,758 D
2026-02-27 Sale : show line 3 in the form 10b5-1 −240 $482.84 $115,882 137,518 D
2026-02-27 Sale : show line 4 in the form 10b5-1 −2,510 $487.13 $1,222,696 135,008 D
2026-02-27 Sale : show line 5 in the form 10b5-1 −3,278 $488.27 $1,600,549 131,730 D
2026-02-27 Sale : show line 6 in the form 10b5-1 −460 $489.32 $225,087 131,270 D
2026-02-27 Sale : show line 7 in the form 10b5-1 −2,725 $490.54 $1,336,722 128,545 D
2026-02-27 Sale : show line 8 in the form 10b5-1 −949 $491.30 $466,244 127,596 D
Open-market sales · 40,000 sh · avg $493.47 · $19,738,855
Loading xslF345X05/wk-form4_1772573657.xml…